Carlotta Antoniotti

9PUBLICATIONS
71CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 08, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Veronica Conca, Daniele Rossini, Carlotta Antoniotti

|Sep 04, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.

Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto

|Apr 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer.

Roberto Moretto, Marco Maria Germani, Martina Carullo

|Jan 08, 2025
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF -mutated metastatic colorectal cancer treated with targeted therapy.

Guglielmo Vetere, Marco Maria Germani, Carlotta Antoniotti

|Jul 17, 2024
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.

Marinde J G Bond, Maarten van Smeden, Koen Degeling

|Jun 12, 2024
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio

Pageof 2

Frequent Collaborators

9 joint publications

Chiara Cremolini

8 joint publications

Filippo Pietrantonio

7 joint publications

Sara Lonardi

6 joint publications

Veronica Conca